CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T-OPENIA：CAR-T 细胞治疗相关血细胞减少
英文原题：CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias.
查看英文原题
CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞是细胞治疗发展的最新形式，可产生有希望的应答，当前已革新部分血液系统恶性肿瘤的管理。自2017年首次获批以来，临床应用迅速发展，除细胞因子释放综合征和免疫效应细胞相关神经综合征外，其他毒性也逐渐显现。细胞减少症在治疗后<30天（“早期”）、30–90天（“短期”）和>90天（“持续期”）均常见，并影响患者照护和医疗资源使用。本文回顾各时间段细胞减少症的病因、相关因素及患者管理要点，以期为临床提供血液学毒性或CAR-T 相关细胞减少症（CAR-T-OPENIA）指南。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the current times.
As the clinical use has progressed rather rapidly since the first approval in 2017, toxicities beyond cytokine release syndrome and immune effector cell-associated neurological syndrome have surfaced. Cytopenias are common in <30 days ("early"), 30-90 days ("short-term") as well as >90 days ("prolonged"); and have clinical implications to patient care as well as resource utilization.
We review the details of etiology, factors associated with cytopenias, and management considerations for patients with cytopenias for each of these time-frames. This would potentially serve as a clinical guide for hematological toxicity or CAR-T-OPENIA, which is commonly encountered with the use of CAR T-cell therapy.
论文信息
- 作者
- Taneja A、Jain T
- 第一作者单位
- Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA.United States
- 通讯作者单位
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA.United States
- 文献类型
- 综述
- 期刊
- EJHaem2022 Jan
- 原文标识
- PubMed 35844301 · DOI 10.1002/jha2.350
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →